This finding is also in line with the study performed by Kotulak-Chrzaszcz et al. [24] and implies the necessity of using the Smo as a potential drug target for ccRCC since low levels of Smo provide a better survival rate. Here, SMO is linked to nonpapillary renal cell carcinoma.